When a train carrying hazardous chemicals derailed in East Palestine, Ohio, in 2023, the resulting fire exposed residents to potentially cancer-causing substances like vinyl chloride, acrolein, and dioxin. The long-term consequences for human health remain uncertain, as cancers often take decades to develop. But there may be a faster way to understand the risks—by studying the dogs who live alongside these residents. Dogs share our environment and, crucially, develop cancer more quickly, making them valuable companions in cancer research and a powerful model for studying the effects of environmental carcinogens.

One of the most compelling aspects of this research is how closely canine cancers mirror those in humans. Scientists have long known that dogs and their owners are exposed to many of the same environmental risks. But recent findings show that the similarities go far deeper. According to researchers, cancers in dogs and humans often develop through remarkably similar genetic pathways. This makes dogs not just sentinels for environmental danger but also effective partners in developing new cancer treatments for people.

Geneticist Matthew Breen of North Carolina State University describes dogs as “mobile BioSentinel organisms,” emphasizing their role in helping scientists understand human health outcomes. I found this detail striking—dogs, often considered family members, are also key allies in biomedical discovery. Their accelerated aging and disease progression allow researchers to obtain insights in a fraction of the time it would take in human studies.

Veterinary and medical researchers have collaborated for years, but this partnership is becoming more intentional and scientifically robust. For instance, techniques to treat osteosarcoma without limb amputation were first developed in dogs. Now, researchers are finding that canine tumors often carry the same mutations as human cancers. In a large-scale study led by genomicist Elinor Karlsson of UMass Chan Medical School, scientists analyzed thousands of tumors from both species. They found that the genetic mutations driving cancer were often present in the same regions of the same genes, including PTEN, a well-known tumor suppressor involved in breast and prostate cancers.

These findings are not just academic. They have real-world implications for treatment. At FidoCure, a California-based company, researchers examined over 1,000 dogs with cancer and discovered that those treated with human drugs targeting specific mutations had higher survival rates. This suggests that therapies effective in dogs may also work in people, and vice versa. Amy LeBlanc, director of the comparative oncology program at the National Cancer Institute, notes that some therapies first tested in dogs are now in clinical trials or approved for human use. These include immunotherapies for brain cancers and drugs for lymphoma and multiple myeloma.

The speed at which canine cancers progress offers another advantage: faster clinical trials. Douglas Thamm of Colorado State University explains that testing a cancer prevention vaccine in humans could take decades—an impractical timeline for most research budgets. But in dogs, the same study can yield results in just five years. His team recently completed a five-year trial involving 804 dogs, and the results are expected by the end of 2025. This kind of rapid feedback loop could significantly accelerate the development of cancer prevention strategies for humans.

Detection techniques are also benefiting from canine research. Golden retrievers, for example, are particularly prone to hemangiosarcoma, a cancer of the blood vessels. Researchers are exploring whether blood tests—known as liquid biopsies—can detect relapse early, allowing for quicker changes in treatment. Cheryl London of Tufts University, who co-leads the project, believes this could improve outcomes for both dogs and humans by enabling more timely interventions.

Beyond treatment and detection, dogs are proving invaluable in identifying environmental cancer risks. Because they live in the same homes, breathe the same air, and walk on the same pesticide-treated lawns as their owners, dogs are exposed to the same potential carcinogens. But they reach the disease stage much sooner, providing an early warning system for humans. Breen and his team have used this principle to investigate bladder cancer. They found that dogs with a specific mutation—BRAF V595E—were more likely to have been exposed to certain chemicals. Using silicone tags worn by the dogs, the researchers identified 25 chemicals more prevalent in dogs with the mutation, including flame retardants and combustion by-products.

This method is now being applied to assess the impact of the East Palestine derailment. Karlsson and colleagues have sent similar silicone tags to about 75 dog owners near the site. If these dogs show elevated cancer-related mutations, it could prompt closer health monitoring for their human companions. It’s a poignant example of how our bond with dogs extends beyond companionship into shared health outcomes and mutual protection.

Importantly, researchers emphasize that the goal is not to experiment on animals, but to help them. Dogs enrolled in these studies often receive cutting-edge care that might otherwise be inaccessible. As Thamm puts it, the aim is to benefit the individual dog while also advancing science. This dual purpose—improving health outcomes for both species—adds a layer of ethical responsibility and compassion to the research.

In sum, dogs are emerging as powerful allies in the fight against cancer. Their genetic similarities to humans, shared environments, and faster disease progression make them uniquely suited to help identify risks, test therapies, and develop detection methods. As science continues to uncover the depth of this interspecies connection, our understanding of cancer—and how to combat it—stands to improve for everyone involved.

Read more at washingtonpost.com